# Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control

> **NCT00393458** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1732 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Indacaterol
- **DRUG:** Formoterol
- **DRUG:** Placebo to indacaterol
- **DRUG:** Placebo to formoterol

## Key facts

- **NCT ID:** NCT00393458
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 1732 (ACTUAL)
- **Last updated:** 2011-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00393458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00393458, "Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00393458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*